Artios Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 121

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $114M

  • Investors
  • 27

Artios General Information

Description

Developer of novel cancer treatments designed to target the deoxyribonucleic acid (DNA) damage response. The company's treatments focus on developing therapies through deoxyribonucleic acid damage response pathways to help mutations in their DNA so that they can evolve, enabling physicians to selectively kill cancer cells through a concept known as synthetic lethality.

Contact Information

Website
www.artios.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • B940 Babraham Research Campus
  • Cambridge CB22 3FH
  • England, United Kingdom
+44 01223
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • B940 Babraham Research Campus
  • Cambridge CB22 3FH
  • England, United Kingdom
+44 01223

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Artios Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 17-Nov-2025 $114M Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 27-Jul-2021 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 09-Aug-2018 $85.1M $118M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 19-Sep-2016 $33M $33M Completed Startup
To view Artios’s complete valuation and funding history, request access »

Artios Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D1
Preference
Series D
Series C
Series B 68,421,054 $0.000013 $1.26 $1.26 1x $1.26 17.02%
Series A 21,000,000 $0.000013 $0.99 $0.99 1x $0.99 5.22%
To view Artios’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Artios Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel cancer treatments designed to target the deoxyribonucleic acid (DNA) damage response. The company's t
Drug Discovery
Cambridge, United Kingdom
121 As of 2025

Basel, Switzerland
 

Pasadena, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Artios Competitors (53)

One of Artios’s 53 competitors is FoRx Therapeutics, a Venture Capital-Backed company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
FoRx Therapeutics Venture Capital-Backed Basel, Switzerland
Meditope Biosciences Formerly VC-backed Pasadena, CA
Complix Venture Capital-Backed Diepenbeek, Belgium
Oncorus Formerly VC-backed Andover, MA
PepGen Formerly VC-backed Boston, MA
You’re viewing 5 of 53 competitors. Get the full list »

Artios Patents

  • 118

    Total Documents Applications and Grants

  • Total Patents Families

  • 34

    Granted

  • 40

    Pending

  • Expiring in next 12 mo

Artios Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202508098-D0 Novel compounds and drug conjugates Pending 23-May-2025
GB-202508100-D0 Novel compounds and drug conjugates Pending 23-May-2025
GB-202508102-D0 Novel compounds and drug conjugates Pending 23-May-2025
GB-202508104-D0 Novel compounds and drug conjugates Pending 23-May-2025
GB-202507366-D0 Novel compounds and drug conjugates Pending 13-May-2025
To view Artios’s complete patent history, request access »

Artios Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Artios Investors (27)

Investor Name Investor Type Holding Investor Since Participating Rounds
Janus Henderson Investors Asset Manager Minority
Angel (individual) Minority
RA Capital Management Asset Manager Minority
Avidity Partners Asset Manager Minority
CaaS Capital Management Hedge Fund Minority
You’re viewing 5 of 27 investors. Get the full list »

Ready to get started?

Request a free trial

Artios FAQs

  • When was Artios founded?

    Artios was founded in 2015.

  • Where is Artios headquartered?

    Artios is headquartered in Cambridge, United Kingdom.

  • What is the size of Artios?

    Artios has 121 total employees.

  • What industry is Artios in?

    Artios’s primary industry is Drug Discovery.

  • Is Artios a private or public company?

    Artios is a Private company.

  • What is the current valuation of Artios?

    The current valuation of Artios is .

  • What is Artios’s current revenue?

    The current revenue for Artios is .

  • How much funding has Artios raised over time?

    Artios has raised $384M.

  • Who are Artios’s investors?

    Janus Henderson Investors, , RA Capital Management, Avidity Partners, and CaaS Capital Management are 5 of 27 investors who have invested in Artios.

  • Who are Artios’s competitors?

    FoRx Therapeutics, Meditope Biosciences, Complix, Oncorus, and PepGen are some of the 53 competitors of Artios.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process